Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia

European Urology

Volumn 42, Issue 3, 2002, Pages 254-261

  Souverein, P C ^a   Herings, R M C ^a,b   Man in 't Veld, A J ^c   De la Rosette, J J M C H ^d   Farmer, R D T ^e   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

adrenoceptor antagonists; Benign prostatic hyperplasia; Finasteride; Ischemic heart disease; Nested case control study

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FINASTERIDE; NITRATE; TAMSULOSIN; TERAZOSIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME INHIBITORS; FINASTERIDE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSTATIC HYPERPLASIA;

EID: 0036715461     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00273-7     Document Type: Article

References (35)

1. The development of human benign prostatic hyperplasia with age
2. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community
3. Tamsulosin, a selective α-1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH)
4. A meta-analysis on the efficacy and tolerability of α-1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
5. Meta-analysis of randomized clinical trials of finasteride
6. Medical therapy for benign prostatic hyperplasia: A review of the literature
7. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
8. Prostatic α-1-adrenoceptors and uroselectivity
9. Selective α-1-adrenoceptor antagonists in benign prostatic hyperplasia: Rationale and clinical experience
10. Overview of alpha-blocker therapy for benign prostatic hyperplasia
11. Symptomatic BPH and hypertension: Does co-morbidity affect quality of life
12. Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): Methodological considerations
13. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme
14. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life
15. Automated record-linkage and other approaches to pharmacoepidemiology in The Netherlands
16. Decline in lung function and mortality: The Busselton Health Study
17. Modeling and variable selection in epidemiologic analysis
18. Association between various drugs used for hypertension and risk of acute myocardial infarction
19. Anti-hypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension
20. Control of blood pressure and risk of first acute myocardial infarction: Skaraborg Hypertension Project
21. The risk of myocardial infarction associated with anti-hypertensive drug therapies
22. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α-1-adrenoceptor subtypes and in human prostate
23. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
24. Does extreme dipping of nocturnal blood pressure in elderly hypertensive patients confer high risk of developing ischemic target organ damage from anti-hypertensive therapy?
25. Hypotension in patients with coronary disease: Can profound hypotensive events cause myocardial ischaemic events?
26. Unstable angina: Current concepts of pathogenesis and treatment
27. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-Year results
28. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia
29. Assessment and control for confounding by indication in observational studies
30. Confounding and indication for treatment in evaluation of drug treatment for hypertension
31. An assessment of the validity of ICD code 410 to identify hospital admissions for myocardial infarction: The Corpus Christi Heart Project
32. The acute myocardial infarction in very elderly
33. Prevalence, determinants, and misclassification of myocardial infarction in the elderly
34. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly